Immune checkpoint blockade, particularly targeting programmed death 1 (PD‐1) and programmed death ligand 1 (PD‐L1), shows promise in treating hepatocellular carcinoma (HCC). Here, PDCD1 is linked to hepatocellular carcinoma.